These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26594036)

  • 41. Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration.
    Roberts TC; Johansson HJ; McClorey G; Godfrey C; Blomberg KE; Coursindel T; Gait MJ; Smith CI; Lehtiö J; El Andaloussi S; Wood MJ
    Hum Mol Genet; 2015 Dec; 24(23):6756-68. PubMed ID: 26385637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
    Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
    Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy.
    Murphy S; Dowling P; Zweyer M; Mundegar RR; Henry M; Meleady P; Swandulla D; Ohlendieck K
    J Proteomics; 2016 Aug; 145():24-36. PubMed ID: 26961938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
    Betts CA; McClorey G; Healicon R; Hammond SM; Manzano R; Muses S; Ball V; Godfrey C; Merritt TM; van Westering T; O'Donovan L; Wells KE; Gait MJ; Wells DJ; Tyler D; Wood MJ
    Hum Mol Genet; 2019 Feb; 28(3):396-406. PubMed ID: 30281092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.
    Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S
    Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.
    't Hoen PA; van der Wees CG; Aartsma-Rus A; Turk R; Goyenvalle A; Danos O; Garcia L; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Pharmacogenomics; 2006 Apr; 7(3):281-97. PubMed ID: 16610940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition.
    Tanihata J; Nagata T; Ito N; Saito T; Nakamura A; Minamisawa S; Aoki Y; Ruegg UT; Takeda S
    Biochem Biophys Res Commun; 2018 Oct; 505(1):51-59. PubMed ID: 30236982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Partial Restoration of Brain Dystrophin and Behavioral Deficits by Exon Skipping in the Muscular Dystrophy X-Linked (mdx) Mouse.
    Zarrouki F; Relizani K; Bizot F; Tensorer T; Garcia L; Vaillend C; Goyenvalle A
    Ann Neurol; 2022 Aug; 92(2):213-229. PubMed ID: 35587226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
    Jearawiriyapaisarn N; Moulton HM; Sazani P; Kole R; Willis MS
    Cardiovasc Res; 2010 Feb; 85(3):444-53. PubMed ID: 19815563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proteomic profiling of x-linked muscular dystrophy.
    Lewis C; Carberry S; Ohlendieck K
    J Muscle Res Cell Motil; 2009 Dec; 30(7-8):267-9. PubMed ID: 20082121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
    Lu-Nguyen N; Dickson G; Malerba A
    Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for antisense modulation of dystrophin pre-mRNA splicing.
    Dickson G; Hill V; Graham IR
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
    Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
    Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The potential of exon skipping for treatment for Duchenne muscular dystrophy.
    Partridge T
    J Child Neurol; 2010 Sep; 25(9):1165-70. PubMed ID: 20519674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy.
    Cacchiarelli D; Incitti T; Martone J; Cesana M; Cazzella V; Santini T; Sthandier O; Bozzoni I
    EMBO Rep; 2011 Feb; 12(2):136-41. PubMed ID: 21212803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dystrophic Dmd
    Krishnan VS; Thanigaiarasu LP; White R; Crew R; Larcher T; Le Guiner C; Grounds MD
    Mol Cell Neurosci; 2020 Oct; 108():103549. PubMed ID: 32890728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
    Takeda S
    Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.